**24 November 2026**

# Corrective Appendix 3Y – Dr Yu-Hung Sebastian Tseng

Cambium Bio Limited (ASX: CMB) (Company) advises the lodgement of a corrective Appendix 3Y in relation to the interests of Non-Executive Director Dr Yu-Hung Sebastian Tseng.

Dr Tseng's Appendix 3X lodged in April 2024 and subsequent Appendix 3Y notices, most recently the Appendix 3Y lodged on 24 March 2026, included shares in the Company held by Zheng Yang Biomedical Technology Co., Ltd. (ZYBT) as an indirect interest of Dr Tseng.

Under section 608(3) of the Corporations Act 2001 (Cth), a person has a relevant interest in securities held by a body corporate only if the person's voting power in that body corporate is above 20% or the person controls it. Dr Tseng, who is Chairman of ZYBT, has confirmed to the Company in writing that his voting power in ZYBT, including that of his associates, is below 20% and that he does not control ZYBT. Accordingly, Dr Tseng does not have a relevant interest in the Company's shares held by ZYBT, and those shares are not included in the attached corrective Appendix 3Y.

ZYBT's holding in the Company is disclosed separately in ZYBT's substantial holder notices, which identify Dr Tseng as an associate of ZYBT. There has been no change in Dr Tseng's own holding of 454,093 fully paid ordinary shares.

The attached corrective Appendix 3Y has been lodged to ensure the Company's disclosures accurately reflect Dr Tseng's notifiable interests as required under the ASX Listing Rules.

**– ENDS –**

## About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialisation, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

## Authorisation & Additional Information

This announcement was authorised for release by the Board of Directors of Cambium Bio Limited.

For further information, please contact:
Company Secretary
Email: info@cambium.bio

*Rule 3.19A.2*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

| | |
|---|---|
| **Name of entity** | **CAMBIUM BIO LIMITED** |
| **ABN** | **13 127 035 358** |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director** | YU-HUNG SEBASTIAN TSENG |
| **Date of last notice** | 24 March 2026 |

**Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Direct or indirect interest** | Direct |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | Not applicable (see Nature of change). |
| **Date of change** | Not applicable. Change in the basis of disclosure confirmed by Dr Tseng on 24 November 2026; no change in Dr Tseng's holding. |
| **No. of securities held prior to change** | 454,093 fully paid ordinary shares held by Yu-Hung Sebastian Tseng |
| **Class** | Fully paid ordinary shares |
| **Number acquired** | Nil |
| **Number disposed** | Nil |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and estimated valuation | Not applicable |

+ See chapter 19 for defined terms.

| | |
|---|---|
| **No. of securities held after change** | 454,093 fully paid ordinary shares held by Yu-Hung Sebastian Tseng |
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Corrective notice. There has been no change in Dr Tseng's own holding. Dr Tseng's previous notices included shares in the Company held by Zheng Yang Biomedical Technology Co., Ltd. (ZYBT) as an indirect interest. Dr Tseng has confirmed to the Company in writing that his voting power in ZYBT, including that of his associates, is below 20% and that he does not control ZYBT. He therefore does not have a relevant interest in the Company's shares held by ZYBT, and those shares are not included in this notice. ZYBT's holding is disclosed in its substantial holder notices, which identify Dr Tseng as an associate of ZYBT. |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | N/A |
| **Nature of interest** | N/A |
| **Name of registered holder (if issued securities)** | N/A |
| **Date of change** | N/A |
| **No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| **Interest acquired** | N/A |
| **Interest disposed** | N/A |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| **Interest after change** | N/A |

## Part 3 – +Closed period

| | |
|---|---|
| **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | N/A |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | N/A |
| **If prior written clearance was provided, on what date was this provided?** | N/A |